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Abstract
Background: Cancer-related abdominal pain 
is a common symptom associated with intra-
abdominal malignancies, especially in patients 
with advanced disease and it has posed a 
significant therapeutic challenge to medical 
practitioners. Typically, cancer pain can be 
managed by following the World Health 
Organization three-step analgesic ladder. 
However, the use of opioids, the mainstay 
treatment for moderate-to-severe cancer-
related pain, may be ineffective in a subset of 
cancer patients. Escalation of dosage may be 
limited by opioid-induced side effects. The 
aim of our study was to review the literature 
addressing the effect of neurolytic celiac 
plexus block (NCPB) on the palliation of 
pain emanating from advanced upper intra-
abdominal malignancies.
Methods: Electronic databases including 
Medline/PubMed, EMBASE, and Cochrane 
Library were searched. Only studies with 
a high level of evidence were reviewed. 
These included prospective randomized 
control studies, systematic reviews and 
meta-analyses. Furthermore, references from 
included articles were carefully reviewed for 
additional relevant trials.
Results: A total of 13 prospective randomized 
trials, five systematic reviews and meta-
analyses, and one Cochrane review article 
were found to meet eligibility criteria.
Conclusion: Neurolysis of the celiac/
splanchnic plexus is an effective and safe 
therapeutic modality that should be considered 
early for palliation of cancer-related pain in 
advanced upper intra-abdominal malignancies. 
This is especially true for patients with 
intolerable opioid-induced adverse events and 
painful symptoms resistant to oral analgesics.
Introduction 
Despite recent advances in diagnostic and 
therapeutic modalities, cancer remains as the 
second leading cause of death in the U.S.1 
Pain is a relatively common cause of cancer-
related disability and the leading contributor 
to poor quality of life (QoL).2 About 25 to 
40% of cancer patients reported dying in 
agony secondary to moderate-to-severe pain 
in their final three days.3,4 With increased life 
expectancy in cancer patients it is important to 
prevent needless suffering through prompt and 
effective pain control, as a significant number 
of cancer victims bear a poor prognosis, 
especially those with advance-staged disease.5 
Thus, in 70 to 80% of patients with advanced 
disease, and up to 90% of those with bone 
metastases, ablative procedures including 
neurolysis of the celiac/splanchnic plexus 
should be sought to improve analgesic 
outcomes.6
Pathophysiology of Cancer-Related Pain
Cancer-related pain can be classified 
as nociceptive, neuropathic, or mixed.7 
Nociceptive pain can be further classified as 
somatic or visceral.7 Somatic pain is described 
as a squeezing or sharp sensation that can 
be localized as a focal point of tenderness.7 
Stimulation of peripheral sensory neurons, or 
nociceptors, by noxious stimuli from tumor 
invasion or compression of adjacent somatic 
structures leads to somatic pain.8,9 On the 
contrary, visceral pain presents in a poorly 
localized, diffuse pattern that is accompanied 
by a deep pressure-like sensation.7,10 It 
can be triggered by smooth muscle spasm, 
distension of hollow viscus or organ capsule, 
chemical irritation, stretching or twisting of 
the mesentery as well as ischemic injury of 
visceral organs.9 Regardless of whether the 
source is visceral or somatic, most patients 
respond favorably to traditional analgesics. 
Effective control of cancer-related 
neuropathic pain remains a challenge as the 
outcome of standard treatment is relatively 
unpredictable.11 Neuropathic pain may be 
perceived as burning, tingling, shooting and/
or lancinating forms of sensation.7 Further, 
difficulties associated with the management 
of neuropathic pain may be multifaceted 
involving peripheral and central sensitization, 
neuroplasticity and modulation of the 
nociceptive somatosensory pathway within 
the central nervous system.12 
Regardless, the mechanism of cancer-related 
pain can be attributed to a multitude of 
mechanical, inflammatory, neuropathic, and 
ischemic factors due to tumor infiltration 
of neural structures, direct compression 
of adjacent tissues, peripheral neuropathy 
from chemotherapy, plexopathy and fibrosis 
from radiation therapy, and chronic post-
surgical pain.9,13 Treatment of cancer-related 
pain can be achieved through multiple 
modalities including pharmacological, 
chemoradiotherapy, palliative surgeries and 
interventional pain therapies.
Pharmacological Management of Upper 
Intraabdominal Malignancies
Traditionally, the mainstay of cancer-related 
analgesia is opioid-based. However, there 
is increasingly more evidence supporting a 
multimodal therapeutic approach.11 In general, 
70 to 90% of cancer-related pain can be 
managed by following the three-step analgesic 
ladder developed by the World Health 
Organization in 1986.14 However, 10 to 20% 
of advanced cancer patients, especially those 
with neuropathic pain and bone metastases, 
remain refractory to standard therapies.3,10,15 
Despite a multimodal pharmacological 
approach, patients with upper intraabdominal 
malignancies frequently experience 
excruciating pain during the course of their 
illnesses and psychological distress at the 
end of life.12 Neurolytic celiac plexus block 
(NCPB) has been proposed as an alternative 
to ameliorating pain in patients with advanced 
upper intraabdominal malignancies.
Relationship between Cancer-Related Pain 
and Survival
Pain frequently creates considerable distress 
in cancer patients. The prevalence of pain 
in cancer patients was alarmingly high, with 
53% of cancer patients at all disease stages 
reporting it.14 Given the tremendous advances 
in cancer therapy, which have resulted in 
better life-expectancy and increased long-term 
survival, the number of individuals suffering 
from cancer pain is bound to increase 
substantially. 
It has long been speculated that uncontrolled 
pain may pose a negative impact on the 
survival of cancer patients. Cancer-related 
pain is postulated to promote tumor growth 
and metastases through a complex interplay 
of cellular pathways and consequently 
shorten survival.16,17 Putative mechanisms 
include attenuation of immune response via 
inhibitory effect on natural killer (NK) cells, 
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stimulation of mitogen-activated protein 
kinase (MAPK) to facilitate tumor growth, 
and chronic activation of mu-opioid receptors 
(MOP-R) from increased level of endorphins 
or frequent use of opioids.16,17 Elevated levels 
of endorphins and exogenous use of opioids 
are thought to be the predominant triggers 
that facilitate these mechanisms, leading to 
reprogramming of tumor cells and thereby 
promoting tumorigenesis.16 
Of note, systemic use of opioids has become 
an integral part of providing high-quality 
palliative care for cancer patients. However, 
numerous in-vitro and in-vivo studies 
have demonstrated a dual effect on cancer 
survival associated with administering 
systemic opioids.18 Several mechanisms 
have been proposed, including tumor cell 
proliferation due to imbalance of pro- and 
anti-apoptotic enzymes, angiogenesis as a 
result of modulation of vascular endothelial 
growth factor (VEGF) signaling, metastasis 
due to changes in matrix metalloproteinases 
(MMP), as well as expression, activity 
level, and neurogenic inflammation due to 
changes in gene expression of inflammatory 
cytokines and receptors.18 Together, these 
studies have highlighted the diametrically 
opposed potentials of opioids in promoting 
or inhibiting tumor proliferation. Given this 
duality, it is not surprising that the association 
between opioid usage and survival in cancer 
patients remains unclear. In addition, the 
common nature of opioid-induced side effects 
and concerns related to tolerance, dependence, 
and aberrant drug-seeking behaviors have 
persuaded many practitioners to seek 
alternatives for effective palliation of cancer 
pain.
Interventional techniques have been 
advocated as safe and effective strategies 
for palliation of cancer-related pain without 
causing intolerable side effects. There is 
accumulating evidence implicating perineural 
invasion of tumor cells in the pathogenesis 
of tumor growth and migration.16 Recent 
evidence from a preclinical study in mouse 
models of pancreatic ductal adenocarcinoma 
demonstrated that early denervation of 
peripheral sensory fibers using capsaicin 
significantly delayed neoplastic growth and 
prolonged median survival by 3.3 months (p = 
0.001).19 Similar findings have been reported 
in other animal models including vagal nerve 
ablation in gastric cancers, sympathectomy in 
prostate cancer, and denervation of the dorsal 
cutaneous nerve in basal cell carcinoma.20,21,22 
Taken together, these models support the 
notion that early surgical or chemical 
denervation such as NCPB may prevent 
neoplastic development, progression, and 
metastasis, resulting in improved pain relief 
and prolonging survival. 
Neuroanatomy of the Celiac Plexus
 The celiac plexus is an extensively 
interconnected network of neural structures 
within the sympathetic nervous system. 
It is formed by paired celiac ganglia and 
autonomic fibers.23 The celiac ganglia supply 
nociceptive and sympathetic efferent outputs 
via thoracic splanchnic nerves to the upper 
abdominal viscera including pancreas, 
gallbladder, diaphragm, liver, spleen, distal 
esophagus, stomach, small bowel, ascending 
and proximal transverse colon, adrenal glands, 
kidneys, abdominal aorta and mesentery.24,25 
Similarly, nociceptive inputs from visceral 
organs carried by afferent fibers will pass 
through the celiac ganglia, thoracic splanchnic 
nerves, and sympathetic ganglia to reach the 
spinal cord. Thoracic splanchnic nerve fibers 
branch off the sympathetic trunk and descend 
medially through the diaphragmatic crura 
along the paravertebral border to synapse with 
celiac ganglia.23 The paired celiac ganglia 
lie medial to the adrenal glands and anterior 
to the descending thoracoabdominal aorta 
bilaterally at T12 and L1 vertebral levels 
in the retroperitoneal space.23,26 Despite 
considerable anatomical variability, the 
greater and lesser splanchnic nerves most 
frequently arise from T5 to T9 and T9 to 
T12 ganglia, respectively; while the least 
splanchnic nerves are formed by nerve roots 
arising from T11 to T12 ganglia.23 
Techniques of Celiac/Splanchnic Nerve Block
The percutaneous celiac/splanchnic nerve 
block has been ubiquitously performed for 
the management of both malignant and 
non-malignant pain involving the upper 
abdominal viscera. The classic approach to 
blocking these afferent nociceptive impulses 
is described as the posterior percutaneous 
retrocrural technique.27 Several modifications 
of this conventional approach have been 
described, which include transcrural,28,29 
transaortic,30 transdiscal,31 and anterior 
approach.32,33 The diaphragmatic crura serves 
as an important landmark for this nerve block. 
Chemical denervation of the celiac plexus 
can be achieved with either a transcrural or 
transaortic approach; while blockade of the 
splanchnic nerves can be accomplished with a 
retrocrural approach.27,34 
Traditionally, the nerve block was performed 
blindly using anatomical landmarks. Trimble 
et al. first reported successful relief of upper 
abdominal malignant pain via blockade of 
the celiac plexus in 1952.35,36 The concept of 
fluoroscopy-guided celiac plexus block was 
introduced by Bonica et al. in 1954.37 Clinical 
application of other advanced imaging 
modalities, such as computed tomography 
(CT), endoscopic ultrasound (EUS), and 
videoscopic thoracoscopy, have also become 
increasingly common to improve needle 
accuracy, increase patient safety, reduce 
catastrophic complications and enhance block 
efficacy. Successful blockade of the celiac 
plexus has also been demonstrated via direct 
injection of neurolytic agent during surgical 
laparotomy.38,39,40,41
Posterior Approach
The patient is placed in prone position. A 
20- or 22-gauge, 12 to 15 cm needle is placed 
approximately 7.5 cm lateral to the midline 
and caudal to the 12th rib on each side.42,43 
The needles are advanced at a 45o angle with 
a slight 15o cephalad direction toward the 
coronal plane. Lateral redirection of the needle 
by gradual increments is required upon bony 
contact of the first lumbar vertebral body. 
Once the needle has walked off the vertebral 
body, the needle on the left side should be 
advanced 1.5 to 2 cm until aortic pulsation 
can be detected. The same is repeated on the 
right side with the needle advancing into the 
retrocrural space (Figure 1)44,45 Incomplete 
sympathetic blockade of the celiac plexus may 
occur with the classic retrocrural approach. 
Penetration of a neurolytic agent through the 
aortic hiatus in the diaphragm is mandatory, 
as demonstrated by Moore et al. in 1981, with 
needle placement posterior and cephalad to 
the diaphragmatic crura.46
The classic retrocrural approach was 
modified to a transcrural technique by Boas 
and Singler.28,29,47 There is no difference in 
terms of needle placement on the left side 
(Figure 2). However, the needle placed on the 
right side will be advanced slightly further, 
about 2 to 3 cm, just enough to penetrate 
ventrally through the right diaphragmatic 
crura. Regardless of whether the approach 
is retrocrural or transcrural, the laterality of 
needle placement on each side prompted the 
search for modified techniques including the 
transdiscal and transaortic approaches (Figure 
3A and B). Both techniques require only one 
needle projecting directly toward the central 
region of the celiac plexus, causing less 
patient discomfort and tissue injury. Contrast 
medium is used to confirm correct placement 
of needles and adequate spreading around the 
T12 and L1 vertebral bodies. A diagnostic 
block of local anesthetic with epinephrine 
should be performed prior to all sympathetic 
neurolysis, consistent with usual standards for 
regional nerve blocks.
Anterior Approach
A modification of the classical approach 
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is the CT- or ultrasound-guided anterior 
approach (Figures. 4 & 5). The intervention 
is performed with the patient supine and 
needle is inserted perpendicular to the skin 
slightly left of midline around the epigastric 
region at 1.5 cm below xiphoid process.48 
The needle is advanced into the precrural 
space immediately anterior to the abdominal 
aorta located between the origins of the 
celiac trunk and superior mesenteric artery.49 
The possibility of tumor cell seeding in the 
needle track should always be considered in 
cancer patients following the trans-pancreatic 
approach. Proper needle placement can be 
confirmed by the spread of contrast within the 
anterolateral aspect of diaphragmatic crura.49 
The purpose of this paper is to review the 
literature addressing the effect of neurolytic 
celiac plexus block (NCPB) on the palliation 
of pain emanating from advanced upper intra-
abdominal malignancies.
Materials and Methods
We conducted an electronic literature 
search in the following databases: Medline/
PubMed, EMBASE, and Cochrane Library 
without specific limitation on the year 
of publication. A search of the available 
literature was performed in November 2017, 
with the assistance of a librarian, using search 
terms that captured publications related to 
cancer pain, efficacy, survival, quality of 
life, celiac plexus, splanchnic nerve, nerve 
block, neurolysis, neurolytic, denervation, 
carcinoma, neoplasm, metastases, cancer-
related and tumor. The number of initial hits 
from these search terms was over 10,000 
articles and was further narrowed down to 
only those that also included the terms celiac 
plexus and/or splanchnic nerve. The authors 
initially reviewed titles and abstracts to find 
the most pertinent studies before full texts 
were read to determine inclusion/exclusion. 
Only prospective randomized control trials, 
systematic reviews and meta-analyses were 
considered for review. All articles written 
in non-English language were excluded. 
A secondary search of the bibliographies 
and citations of all included articles was 
performed to ensure inclusion of all relevant 
articles. 
Results 
A total of six randomized controlled trials 
(RCTs), one prospective randomized 
uncontrolled trial, one prospective non-
randomized controlled trial, one Cochrane 
review, and five systematic reviews and/
or meta-analyses were eligible for review 
of the efficacy of NCPB. There were two 
Figure 1. Computed tomography showing proper positioning of spinal needle in the right retrocrural 
space. [Reprinted by permission from the Rightslink service of CCC: Springer Nature, Abdominal 
Imaging. CT-guided percutaneous neurolytic celiac plexus block technique. Wang PJ, Shang MY,  
Qian Z et al. 2006.]
Figure 2. Computed tomography showing the transcrural technique with placement of spinal needle 
tip just pass the left diaphragmatic crura. [Reprinted by permission from the Rightslink service of 
CCC: Springer Nature, Abdominal Imaging. CT-guided percutaneous neurolytic celiac plexus block 
technique. Wang PJ, Shang MY, Qian Z et al. 2006.]
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Figure 3. The A-P (A) and lateral (B) views demonstrating contrast spread in the retrocrural space with the unilateral, single-needle transdiscal approach. 
[Computed tomography (CT) simulated fluoroscopy-guided transdiscal approach in transcrural celiac plexus block by Kong GY et al. Copyright 2013 by The 
Korean Pain Society. Reprinted by permission under the terms of Creative Common License CC BY-NC 3.0]
Figure 5. Ultrasound-guided technique showing the celiac trunk (T) and abdominal aorta (A). Needle 
tip is placed immediately anterior to the abdominal aorta (dark arrows) between the celiac trunk and 
mesentery artery (S). [Coeliac plexus neurolysis for upper abdominal malignancies using an anterior 
approach: review of the literature by Ghai A et al. Copyright 2015 by Medpharm Publications, NISC 
(Pty) Ltd and Cogent, Taylor & Francis Group. Reprinted by permission under the terms of Creative 
Common License CC BY-NC-ND 4.0
Figure 4. Computed tomography demonstrating 
the transpancreatic approach with appropriate 
spread of contrast immediately anterior to 
the abdominal aorta along the celiac axis. 
[Coeliac plexus neurolysis for upper abdominal 
malignancies using an anterior approach: review 
of the literature by Ghai A et al. Copyright 2015 
by Medpharm Publications, NISC (Pty) Ltd and 
Cogent, Taylor & Francis Group. Reprinted 
by permission under the terms of Creative 
Common License CC BY-NC-ND 4.0]
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prospective randomized studies that compared 
the efficacy of celiac plexus block with 
splanchnic nerve block. There were four 
prospective studies related to the effect of 
NCPB on QoL and five prospective studies 
related to the effect of NCPB on survival 
(Table 1). One RCT was found that detailed 
different volumes of alcohol in celiac plexus 
block. There was only one retrospective study 
comparing the effectiveness of alcohol and 
phenol in NCPB. 
Discussion
Efficacy of Celiac/Splanchnic Plexus 
Neurolysis Prospective Clinical Trials
Neurolytic blockade of the celiac plexus 
was originally reported by Kappis in 1914.50 
However, the first prospective randomized 
control study was not published until 1992.51 
Ischia and associates evaluated 61 patients 
with unresectable pancreatic cancer who were 
randomized to undergo one of the 3 posterior 
percutaneous approaches to NCPB, namely, 
transaortic, classic retrocrural, and bilateral 
chemical splanchniectomy. They reported 
abolition of cancer-related celiac pain in 75% 
of patients immediately post-NCPB and up 
to 67% of patients at the time of death (p < 
0.01). Interestingly, they found that only 10-
24% of patients had complete pain relief from 
NCPB alone at the time of death, but up to 
80-90% when combined with other therapies, 
suggesting the clinical significance of a 
multimodal analgesic approach. The authors 
concluded that there was no statistically 
significant difference in efficacy, morbidity, 
performance status, survival rate, and type of 
recurrent or residual pain among these three 
techniques. 
A smaller RCT of 20 patients with advanced 
pancreatic cancer was performed to 
investigate the effectiveness of NCPB in 
alleviating severe cancer-related pain.52 This 
pilot study by Mercadante in 1993 compared 
the effectiveness of NCPB to traditional 
nonsteroidal anti-inflammatory drugs 
(NSAIDs) and opioid treatment on cancer-
related pain relief. Overall, both NCPB and 
systemic analgesic therapy (SAT) provided 
statistically significant reductions in visual 
analogue scale (VAS) pain scores and opioid 
dosage requirements at all seven weekly 
follow-up intervals up to the time of death. 
The authors concluded that NCPB may be 
more desirable than SAT because of less 
opioid-induced side effects.
The largest single center, double-blinded RCT 
by Lillemoe and colleagues provided high-
quality, level-one evidence.53 Among the 137 
patients evaluated, chemical splanchniectomy 
with alcohol significantly reduced mean pain 
scores at 2, 4, and 6 months, and within two 
months of death, especially for those with 
significant preoperative pain (p ≤ 0.05). Time 
to rescue with NCPB was also substantially 
longer in the NCPB group compared to the 
SAT group (11.8 vs. four-months; p ≤ 0.05). 
Despite improved mood and lower disability 
scores in patients receiving alcohol, there was 
no statistically significant difference between 
the alcohol and saline group. Adverse events 
were reportedly minor and self-limited. 
Their findings support the efficacy and safety 
of intraoperative alcohol splanchniectomy 
in advanced pancreatic cancer patients for 
attaining favorable outcomes, including 
significantly lower mean pain scores, lower 
analgesic consumption, longer duration of 
pain relief, and lower incidence of significant 
pain at death. 
Kawamata et al. published a pilot RCT of 
21 patients with pancreatic cancer in 1996, 
highlighting the effect of NCPB on health-
related QoL.54 Consistent with the outcomes 
from previous studies, NCPB significantly 
reduced VAS pain score during first four 
weeks immediately after the procedure 
compared to SAT (p < 0.05). Morphine 
consumption was found to be substantially 
reduced from week four to seven after NCPB 
(p < 0.05). 
In an RCT published in 1998, Polati et 
al. performed NCPB in 24 patients who 
had unresectable pancreatic cancer over a 
two-year period.55 They found complete 
pain relief within 24 – 48 hours after NCPB 
in 75% of patients compared to merely 
17% in SAT (p < 0.05). There was also a 
significant reduction in diclofenac use, opioid 
consumption, and drug-related adverse events 
in patients with NCPB. Notably, the complete 
abolition of pain was achieved in only one 
patient with NCPB alone, but nine patients 
when combined with SAT. This finding was 
consistent with those reported by Ischia and 
associates, supporting the clinical importance 
of a multimodal analgesic therapy. Despite 
favorable outcomes in the reduction of VAS 
pain score and oral analgesic use within 24 – 
48 hours of treatment, the long-term results 
were not significantly different between the 
two groups.
Wong et al. conducted a prospective, double-
blinded RCT evaluating the effect of NCPB 
on pain relief and opioid consumption 
involving 100 patients with unresectable 
pancreatic cancer.56 Both NCPB and 
SAT substantially reduced pain intensity 
compared to baseline, with the NCPB group 
demonstrating a significantly greater pain 
reduction than the SAT group (53% vs. 27%, 
p = 0.005). Sustained analgesic benefits of 
NCPB lasted until the time of death. There 
was a gradual increase in opioid usage due 
to tumor progression. Contrary to previous 
studies,52,54,55 there was no significant 
difference in opioid consumption between 
NCPB and control (p = 0.93).
Jain et al. reported similar outcomes in 
100 consecutive patients with advanced 
malignancies suffering from upper 
abdominal pain or backache.57 These patients 
demonstrated superior analgesic benefits from 
NCPB compared to SAT, where the VAS 
pain score was significantly lower at 7 and 
30 days after NCPB (p = 0.03 and p = 0.005, 
respectively). Consistent with most studies, 
mean consumption of morphine was lowered 
by 50% at the 30-day interval in the NCPB 
group (p = 0.00), with 31% of these patients 
requiring only non-opioid and other adjuncts 
for pain relief. The major weakness of this 
study was imposed by the limitation of a non-
randomized and non-blinded design. 
The efficacy of CT-guided NCPB was 
assessed in a randomized control trial 
by Zhang et al. involving patients with 
unresectable pancreatic cancer.58 All 56 
patients who received either CT-guided NCPB 
or SAT obtained significant reduction in VAS 
pain score at 1, 7, 14, 30, 60, and 90 days 
after treatment compared to baseline VAS 
pain score (p < 0.01). A significant difference 
in the reduction of VAS pain score between 
the two groups was found at only 1, 7, and 
14 days after treatment (p < 0.01). Morphine 
requirement was also significantly lower in 
patients with NCPB at 7, 14, 30, 60, and 90 
days after treatment compared to patients with 
SAT (p < 0.01). The authors concluded that 
CT-guided NCPB with alcohol is effective 
for treatment of intractable pancreatic cancer 
pain. 
Systematic Review and Meta-Analysis
Eisenberg and colleagues conducted the first 
meta-analysis to assess the efficacy and safety 
of NCPB in patients with intraabdominal 
malignancies.59 This meta-analysis pooled all 
data published in 21 retrospective studies, one 
prospective study, and two RCTs from 1966 to 
1993, which involved a total of 1145 patients 
with either pancreatic (63%) or non-pancreatic 
(37%) intraabdominal malignancies. The 
authors found that NCPB provided both short- 
and long-term analgesic efficacy in 89% (95% 
CI: 86.9-90.9) and 90.2% (95% CI: 77.9-96.3) 
of patients, respectively. Importantly, 6 of 
the 24 studies demonstrated either partial 
or complete pain relief in 73% and 92% of 
patients, respectively. The reasons underlying 
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61 Transaortic celiac 
plexus block vs. 
classic retrocrural 










of recurrent or 
residual pain  
Transaortic – 30 
ml of absolute 
alcohol via each 
needle; classic 
retrocrural – 15 ml 
of absolute alcohol 
via each needle; 
bilateral chemical 
splanchniectomy 
– 7 ml of absolute 
alcohol via each 
needle
There was no statistically significant difference in 
efficacy and morbidity among the three-posterior 
percutaneous NCPB. Success rate was reported 
to be 70-80% immediately after procedure and 
60-75% at the time of death.
Transient, minor complications 
were self-limited, which 
include diarrhea, dysesthesia, 
reactive pleurisy, hiccoughing, 
and hematuria. Orthostatic 
hypotension was reported in all 
three techniques but significantly 
less likely with transaortic 
approach. No operative mortality 
was reported.
NCPB is an appropriate 
percutaneous technique for 










of NSAID and 
opioid analgesic 
therapy
20 NCPB vs. SAT VAS pain 
score, opioid 
consumption
25 ml of 75% 
alcohol bilaterally
There was significant reduction of baseline 
VAS score in both treatment groups by the 8th 
week or at the time of death. However, there 
was no significant difference in VAS score 
between the two treatment groups. Patients who 
received celiac plexus block required less opioid 
consumption for the following 8 weeks or up to 
the time of death.
There was one case of prolonged 
diarrhea requiring octreotide, two 
cases of orthostatic hypotension 
lasting 48 hours requiring 
vasopressors, and one case of 
back pain at the needle entry site.
NCPB is safe and reduces 
opioid consumption for pain 















with 50% alcohol 








20 ml of 50% 
alcohol bilaterally
Intraoperative chemical splanchniectomy with 
alcohol resulted in significant improvement in 
mean pain score at 2-, 4-, and 6-month, and final 
assessment within 2 months of death compared 
to control group. Patients who received alcohol 
treatment had significantly longer duration of 
pain relief, lower narcotic requirement, and less 
likely to have severe pain at death. Scores for 
disability and mood progressively worsened over 
the clinical course of disease for all patients. No 
significant difference was found in mood and 
disability score between the alcohol and control 
group. Survival was found to be markedly 
improved in alcohol group when compared to 
control group (p<0.0001). 
There were two cases with 
transient episodes of hypertension 
without sequelae during 
alcohol injection. There was no 
complication associated with 
hypotension or bleeding following 
any celiac plexus injection. 
Intraoperative chemical 
splanchniectomy with 
alcohol should be 

















15-20 ml of 80% 
alcohol bilaterally
VAS score was significantly lower for the first 
4 weeks after NCPB compared to NSAID-
Morphine treatment. Morphine consumption was 
found to be significantly lower in NCPB group 
than those in NSAID-morphine group at 4-7 
weeks post-procedure. Statistically significant 
improvement in performance status was found 
only at 4th week between the two groups.
Symptoms of loss of appetite 
at 6th and 8th week and nausea 
at 8th week were found to be 
significantly higher in NSAID-
morphine group. 
Improvement in pain 
management may not 
correlate with better 
quality of life in advanced 
pancreatic cancer patients.
















7 ml of absolute 
alcohol via each 
needle
Primary endpoint was immediate (24-48 h) and 
long-term efficacy of the treatment until death. 
Complete pain relief at 24- and 48-h interval was 
reported in 9 out of 12 patients in NCPB group 
but only 2 out of 12 patients in pharmacological 
therapy group. However, long-term pain relief 
was not significant between the two groups. 
Mean consumption of NSAID and opioid was 
significantly lower in NCPB group
Transient diarrhea and orthostatic 
hypotension were observed in 3 
and 5 patients who underwent 
NCPB, respectively.
Neurolytic celiac plexus 
block can abolish visceral 
celiac type of cancer-
related pain in a significant 
portion of pancreatic cancer 
patients. It also reduces the 
incidence of drug-related 
adverse events due to lower 
opioid consumption.











with 50% alcohol 









of daily living, 
survival rate
20 ml of 50% 
alcohol bilaterally
There was significant reduction in VAS pain 
score in alcohol group compared to saline 
group. Alcohol block also significantly improved 
longevity compared to saline block. High 
negative mood patients were correlated to 
more pain interference with daily activities. 
Postoperative pain score was found to be 
inversely correlated with longevity, and the 
correlation was significant.
N/A Bilateral splanchniectomy 
with alcohol during surgical 
laparotomy improved 
pain, mood, activities, and 












body and/or tail of 
pancreas








40 ml of 75% 
ethanol for NCPB 
and 6 ml of 75% 
ethanol for bilateral 
splanchnic nerve 
blockade
Splanchnic nerve block provided significantly 
greater VAS difference, lower opioid 
requirement, and greater survival rate than 
celiac plexus block. However, QoL was found to 
be insignificant between the two groups.
Two patients in celiac group and 
one patient in splanchnic group 
reported severe pain during 
procedure. Five patients in 
celiac group developed transient 
diarrhea. Two patients in celiac 
group required inotropic support 
for hemodynamic instability.
Splanchnic nerve blockade 
may be more effective than 
celiac plexus blockade in 
patients with advanced 
cancer with tumor involving 
the pancreatic body and tail.














10 ml of absolute 
alcohol via each 
needle
Mean pain intensity was significantly reduced in 
both groups as early as 1 week after treatment. 
The reduction in pain was significantly greater in 
NCPB than SAT group. QoL gradually declined 
after one-week post-treatment in both groups 
with no significant difference between the two 
groups. Opioid consumption increased over 
time with no difference between the two groups. 
No significant difference in survival was found 
between treatment groups. 
N/A NCPB improves pain relief 
in patients with pancreatic 
cancer compared to SAT 
but not QoL and survival.












20 ml of 50% 
alcohol 
VAS score was significantly lower in NCPB 
group than that of control group at 7 and 30 
days after treatment. Morphine consumption was 
significantly lower in NCPB group compared to 
that of control group at 30 days after treatment. 
Quality of life was significantly improved in 
NCPB group but not statistically different from 
control group at 30 days.
Celiac plexus neurolysis 
statistically lowers pain intensity, 
reduces morphine consumption, 
and improves QoL at 30-day 
interval, but there was no 
significant difference in QoL when 
compared with morphine group
Side effects of treatment 
were significantly higher in 
morphine group.















20 ml of absolute 
alcohol
Patients who underwent NCPB had significantly 
lower VAS pain score than those at 1, 7, and 
14 days. Opioid consumption was significantly 
lower in NCPB than control group at day 7, 
14, 30, 60, and 90 days. Quality of life was 
significantly improved after treatment, but no 
significant difference was found between the 
two groups.
Orthostatic hypotension, 
drunkenness symptoms, diarrhea, 
and burning pain at needle entry 
site were reported. Only 6 patients 
who underwent NCPB had 
nausea and vomiting compared to 
22 patients in control group, which 
was significantly different.
CT-guided NCPB is safe 
and effective modality for 
cancer-related pain relief in 
advanced pancreatic cancer 
patients.
VAS – Visual Analog Scale; NRS – Numeric Rating Scale; NCPB – Neurolytic Celiac Plexus Block; SAT – Systemic Analgesic Therapy; QoL – Quality of Life; NSAID – nonsteroidal anti-inflammatory drug; 





















































































List of prospective studies evaluating the effect of neurolytic celiac/splanchnic plexus blockade on pain reduction, opioid consumption, quality of life, and/or 
survival in patients with advanced intraabdominal malignancies. 
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the inter-patient discrepancy between partial 
and complete pain relief could be multi-fold 
and possibly related to incomplete destruction 
of the celiac plexus. As demonstrated by 
postmortem neurohistological studies of the 
celiac plexus, evidence of perineural fibrosis, 
shrunken-looking neurons, normal-appearing 
nerve fibers, and lymphocytes in pancreatic 
cancer patients after NCPB implied the 
very common nature of incomplete celiac 
neurolysis.60 Other proposed theories 
included the coexistence of more than 
one source of pain, insufficient spread of 
neurolytic agent, and migration of tumor cells 
into surrounding tissues.51 
One multi-centered study prospectively 
examined the predictors of successful 
response to NCPB in 22 patients with 
pancreatic cancer pain. Mercadante and 
associates concluded that the experience 
of the physician and local spread of the 
tumor are likely the predominant factors 
contributing to the outcomes of NCPB.61 
Unsatisfactory responses to repeated trials 
of NCPB have also been demonstrated 
by CT in patients with massive invasion 
and metastases around the celiac axis.62 A 
pilot study conducted by McGreevy et al. 
also confirmed the significance of disease 
progression and metastases in predicting the 
outcome for repeat NCPB.63 De Cicco et al. 
divided the celiac axis into four quadrants and 
demonstrated that only complete neurolytic 
spread of all four quadrants could guarantee 
long-lasting analgesia, indicating the clinical 
significance of injectate spread for predicting 
the efficacy of NCPB.64 Furthermore, 
Rykowski et al. revealed that the location 
of the pancreatic tumor was an independent 
prognostic factor for predicting the efficacy 
of NCPB. Of the 37 patients (74%) who 
responded favorably to NCPB, 33 patients 
had a tumor involving the head of pancreas 
and four patients had a tumor involving 
the body and tail of the pancreas.62 Their 
findings suggested that the location of tumor 
involvement in the pancreas correlates to 
disease progression and alters the efficacy of 
NCPB.
It is interesting to note that regardless of 
whether radiographic guidance was used 
for NCPB, Eisenberg et al. reported no 
difference in the rate of successful blockade 
and incidence of adverse events.59 Similarly, 
McGreevy et al. compared CT-guided to 
fluoroscopy-guided NCPB and reported no 
significant difference between responders 
and non-responders to repeat NCPB.63 
However, Erdek et al. found that NCPB with 
CT-guidance was correlated with positive 
outcomes, but the results were marginally 
significant (p < 0.06).65 Compared to 
fluoroscopy, CT provides images with higher 
spatial resolution and thereby enhances 
visualization of the celiac ganglia, tumor 
burden, and needle position. Despite higher 
radiation exposure from CT, these advantages 
assuredly attribute to the higher likelihood 
of achieving superior analgesia from NCPB. 
Overall, Eisenberg et al. concluded that NCPB 
is a relatively safe intervention for short- and 
long-term palliation of cancer-related pain in 
patients with intraabdominal malignancies.
A 2007 review by Yan and Myers included 
302 patients from 5 RCTs conducted during 
the period extending from 1966 to 2005.66 
The authors found only 6% reduction in 
pain intensity from NCPB compared to 
baseline pain score. Nevertheless, there was 
a significant mean reduction of 40 to 80 mg 
daily dose of opioid in NCPB compared to 
SAT at two, four and eight weeks, which 
was based on data extracted from three 
studies.52,54,56 Similar to Eisenberg et al., 
the authors concluded that NCPB is a safe 
technique to be incorporated in the standard 
treatment of patients with inoperable 
pancreatic cancer for effective reduction 
in pain intensity, analgesic requirements, 
and opioid-induced constipation.66 Another 
systematic review by Moor and Adler was 
performed in 2009.67 However, no literature 
search criteria were described for the selection 
of appropriate studies. Regardless, they also 
concluded that NCPB is a safe technique that 
provides long-lasting, opioid-sparing benefits 
in pancreatic cancer patients.
A Cochrane Review by Arcidiacono et al. 
evaluated 358 participants included in six 
RCTs.68 There was profound reduction in 
opioid consumption, lower incidence of 
diarrhea or constipation, and improvement in 
immediate pain relief with a weighted mean 
difference of -0.42 at four weeks between 
NCPB and SAT groups (p = 0.004). Despite 
the lack of strong evidence supporting the 
therapeutic superiority of NCPB over SAT 
in pancreatic cancer patients, the authors 
highlighted the clinical significance of 
incorporating NCPB as an opioid-sparing 
strategy to abate opioid-related adverse 
effects.
A systematic review by Nagels et al. identified 
five RCTs, which included results for 295 
patients.69 The meta-analysis demonstrated 
significant differences of -0.87 and -0.47 
in pain reduction when NCPB (n = 149) 
was compared to SAT (n = 146) at one to 
two weeks (p = 0.004) and four weeks (p = 
0.0001), respectively. However, significant 
differences in pain intensity between the two 
groups dissipated at 8 (p = 0.16) and 12 weeks 
in four and two relevant studies, respectively. 
Both NCPB and SAT groups exhibited 
significant reduction of opioid consumption 
compared to baseline. Significant difference 
in the reduction of opioid consumption was 
also found between the two groups at all of 
the time intervals. The mean difference in 
morphine usage was reported to be -44.64 
at one to two weeks (p = 0.002), -72.41 at 
4 weeks (p < 0.00001), and -65.69 at eight 
weeks (p < 0.0001). Only one study had 
data available at 12 weeks, which reported a 
significantly lower consumption of morphine 
in NCPB group compared to SAT group (105 
± 65 mg vs. 169 ± 71 mg; p < 0.01). The 
authors concluded that percutaneous NCPB 
is safe and capable of delivering superior 
analgesic benefits to patients with advanced 
upper intra-abdominal cancer.
Another meta-analysis by Zhong et al. 
examined 7 RCTs, which included 196 
patients who met eligibility criteria.70 Among 
the four studies with the assessment of pain 
score at four weeks, there was a statistically 
significant mean difference in pain score of 
-0.382 between NCPB (n = 99) and SAT (n 
= 98) (p = 0.005). At 8 weeks, the statistical 
significance of mean difference in pain 
score between NCPB (n = 184) and SAT 
(n = 195) was no longer maintained based 
on 6 relevant studies. Regarding the use of 
pharmacological analgesics, there was a mean 
difference of -49.77 (p = 0.005) and -48.29 
(p < 0.001) between NCPB and SAT groups 
at four weeks and one day before death, 
respectively, based on five relevant studies. 
Of the studies included in this meta-analysis, 
NCPB was performed by percutaneous 
NCPB, EUS-guided NCPB, thoracoscopic 
splanchniectomy, and intraoperative 
chemical splanchniectomy. The impact of 
these approaches to performing NCPB on 
the efficacy of pain relief remains largely 
unknown due to the dearth of comparative 
studies among these interventions.69 In 
summary, albeit concerns about the potential 
effects of confounding bias, this systematic 
review demonstrated statistically significant 
short-term (four weeks) efficacy of NCPB in 
cancer-related pain and that the efficacy was 
further supported by significantly decreased 
consumption of opioid and NSAIDs.69,70
Efficacy of Celiac Plexus Neurolysis vs. 
Splanchnic Nerve Neurolysis
Innervations of the upper abdominal viscera 
are mediated by sensory afferent and 
sympathetic efferent fibers via the splanchnic 
nerves and celiac ganglia.23 Theoretically, 
blockade of either the celiac ganglia or 




















































































Graduate Medical Education Research Journal21 Review
transmission of the upper abdominal viscera. 
A total of two prospective, randomized, 
comparative studies of percutaneous celiac 
plexus and splanchnic nerve blockade on the 
efficacy of cancer-related pain relief were 
found in the literature. Ischia and colleagues 
explored the efficacy of percutaneous NCPB 
using three different techniques, namely, 
transaortic celiac plexus block, classic 
retrocrural block, and bilateral chemical 
splanchiectomy on pain relief. They found no 
significant difference in pain reduction among 
the three techniques.51 
Özyalçin and colleagues conducted a 
comparative study on the efficacy of celiac 
plexus and splanchnic nerve blockades in 
pancreatic cancer patients.71 This prospective, 
single-blinded, randomized study enrolled 
39 patients with pancreatic adenocarcinoma. 
Patients who received bilateral splanchnic 
nerve blockade reported a significantly greater 
VAS pain score reduction than those with 
celiac plexus blockade up to 12-weeks after 
intervention (p ≤ 0.002). These patients also 
had a more substantial decrease in total daily 
codeine requirement up to 10 weeks after 
treatment (p ≤ 0.041) and increase in survival 
rate (p = 0.0072). Surprisingly, no difference 
in QoL was clinically observed between celiac 
and splanchnic nerve blocks. The authors 
concluded that splanchnic nerve blocks may 
be a viable alternative to celiac plexus block 
based on statistically better outcomes in pain 
reduction, opioid usage and longevity. These 
two small, but otherwise good quality trials 
did not provide sufficient evidence that celiac 
plexus and splanchnic nerve neurolysis differ 
in their relative efficacy. 
Effect of Celiac Plexus Neurolysis on Quality 
of Life and Survival 
Despite the clinical benefit in the palliation 
of cancer-related pain, the effect of NCPB on 
QoL and survival in patients with advanced 
intraabdominal malignancies remains largely 
controversial. Kawamata et al. performed a 
pilot study comparing NCPB with SAT on the 
effect of QoL.54 Despite profound reduction 
in pain and opioid consumption in NCPB 
group, QoL only improved at the two-week 
interval. Gradual deterioration in QoL was 
observed over time with disease progression. 
We can infer that pain severity and opioid 
use do not wholly contribute to QoL, which 
can also be influenced by physiological 
variables, symptom status, functional health 
and general health perceptions.72 Both Jain et 
al. and Zhang et al. found that as an effective 
analgesic intervention, NCPB provided no 
significant difference in improving QoL 
compared to opioids alone.57,58 Despite these 
discouraging outcomes, most practitioners 
remain inclined to attribute the experience of 
suboptimal pain control to deleterious effects 
on all aspects of QoL in cancer patients of all 
stages.
Cancer-related pain is a common and highly 
debilitating symptom associated with 
functional, cognitive, and psychological 
impairments.3,73 Theoretically, optimal 
pain control should promote restoration of 
physical well-being and functional capacity 
in cancer patients. With less psychological 
distress, fatigue, and functional impairment, 
cancer patients can undergo therapies to ease 
symptoms and prolong survival.73 Ischia and 
colleagues found no significant difference in 
survival times in 61 patients with unresectable 
pancreatic cancer after NCPB.51 Surprisingly, 
Lillemoe et al. evaluated 137 patients and 
found that survival was markedly improved 
with alcohol splanchniectomy compared to 
those in the saline group (p < 0.0001).53 Staats 
et al. completed a randomized control trial 
involving 139 participants with unresectable 
pancreatic cancer.74 Among 130 patients 
who completed the study, it was noted that 
NCPB with alcohol during laparotomy had 
a significantly positive impact on longevity 
compared to those with saline (p < 0.01). 
The study also found a negative correlation 
between post-procedural cancer-related pain 
and survival. The authors postulated that 
improved survival might be attributed to 
better QoL including better sleep quality and 
appetite, improved mood, enhanced functional 
capacity and reduced risks of thrombotic 
events. 
Despite the encouraging outcomes on 
longevity by Staat et al. and Lillemoe et al., 
Wong and colleagues conducted a randomized 
control trial with contradictory findings.56 
Their study evaluated the effect of NCPB on 
pain relief, QoL, and survival in 100 patients 
with unresectable pancreatic cancer. Despite 
significant short-term pain reduction, NCPB 
did not offer significant benefits on either QoL 
(p = 0.46) or survival (p = 0.26) within the 
12-week follow-up period. QoL was found to 
gradually decrease with time. By the end of 
the double-blind phase, only 16% of NCPB 
patients and 6% of SAT patients remained 
alive, with no significant difference in survival 
rate between the two groups, implying the 
lack of correlation between pain reduction and 
survival. 
Özyalçin and colleagues compared the 
analgesic efficacy of celiac plexus block 
and splanchnic nerve block and reported 
no significant difference in QoL between 
the two groups on the basis of performance 
status and patient satisfaction.71 Interestingly, 
patients with tumor involving the body and/
or tail of pancreas who underwent splanchnic 
nerve blockade had significantly higher mean 
survival rate (68.85 ± SE 7.3 days) than 
those who underwent celiac plexus blockade 
(45.37 ± SE 5.82 days; p = 0.0072). The 
results implied that greater pain reduction, 
lower opioid consumption and longer life-
expectancy in the splanchnic group may be 
independent of QoL.
In a systematic review by Yan and Myers, the 
evidence did not support any clinical benefits 
in survival rates and QoL despite better pain 
control and less opioid use from NCPB.66 In 
a more recent systematic review by Nagels,69 
improved QoL score from baseline was 
detected initially in two relevant studies but 
deteriorated gradually over time with disease 
progression.54,71 None of the RCTs exhibited 
any significant difference in QoL between 
percutaneous NCPB and SAT.
Overall, NCPB has not convincingly 
been demonstrated to improve QoL and 
prolong survival in patients with upper 
intra-abdominal malignancies. These 
findings may be due to tumor progression 
in advanced disease. A recent preclinical 
study has provided insights into the basis 
of neural-tumor interactions. Saloman et al. 
demonstrated that sensory neuron ablation 
by injection of capsaicin in two mouse 
models of pancreatic ductal adenocarcinoma 
prevented neurogenic inflammation, 
delayed tumor progression and significantly 
prolonged survival (7.80 vs. 4.53 months, 
p = 0.0001).75 Denervation of primary 
afferents that innervate the pancreas can block 
perineural invasion, astrocyte activation and 
neuronal damage, resulting in suppression of 
tumorigenesis in early stages of pancreatic 
cancer.76 These experimental findings support 
the clinical significance of NCPB in the 
early stages of pancreatic cancer to prolong 
survival, and explain the minimal benefits on 
overall survival in patients with inoperable 
pancreatic cancer.
Volume of Neurolytic Agents in Celiac Plexus 
Blockade
Neurolytic agents, especially alcohol, have 
been described to cause neural destruction of 
the celiac/splanchnic plexus for pain relief in 
cancer patients. However, optimal volume of 
neurolytic agent remains to be established. 
In clinical practice, administration of 10-80 
ml of alcohol has been cited for NCPB, with 
typical volumes ranging from 20 to 40 ml.77,78 
Within the literature, there is only one RCT 
exploring the effect of different volumes of 
alcohol on cancer-related pain reduction.79 
Dolly and colleagues selected 30 patients with 
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upper abdominal malignancies as candidates 
for NCPB. The results showed that 20, 30, 
and 40 ml of 70% alcohol provided a duration 
of blockade lasting eight, 12, and 16 weeks, 
respectively. Forty mililiters of injectate was 
found to have a significantly lower morphine 
requirement and higher QoL scores compared 
to 20 and 30 ml. These outcomes validated 
the rationale proposed by De Cicco et al. that 
thorough spread of alcohol, involving all four 
quadrants of the celiac axis, was essential 
to achieve complete pain relief.64 Therefore, 
the possibility of volume to affect the spread 
of neurolytic agent is certainly plausible for 
predicting the outcome in pain reduction, 
analgesic usage and QoL. Given the paucity 
of studies further large-scale randomized trials 
are needed to address the optimal volume of 
neurolytic agent to administer during NCPB. 
Types of Neurolytic agents in Celiac Plexus 
Blockade
Neurolytic agents such as phenol and 
alcohol have been used extensively to induce 
disintegrative nerve changes via Wallerian 
degeneration, promoting long-lasting 
analgesia, reportedly up to six months.80,81,82,83 
The extent and duration of analgesia after 
ablation are frequently limited by axonal 
regeneration, which begins within three 
to six months at a rate of 1 to 1.5 mm per 
week.80,81,82,83,84 Concentrations of 50-100% 
alcohol and 6-10% phenol have been used 
successfully for chemical ablation of neural 
structures.24,85 Koyyalagunta and colleagues 
retrospectively evaluated 93 patients with 
abdominal cancer pain.86 The authors found 
no significant difference in pain reduction 
at one month between alcohol and phenol 
use for NCPB (p = 0.66). There was also 
no difference in complications between the 
two agents. The authors demonstrated that 
both neurolytic agents were equally effective 
and safe for cancer-related pain relief. With 
limited evidence, prospective randomized 
studies are needed to validate that both 
alcohol and phenol are equally effective in 
NCPB.
Safety of Celiac Plexus Neurolysis 
Eisenberg et al. reported that adverse events 
including local pain (96%), diarrhea (44%), 
and hypotension (38%) were common but 
transient, self-limited and of mild severity.59 
Severe neurological complications accounted 
for an estimated incidence of 1% and included 
lower extremity weakness, paresthesia, 
epidural anesthesia and lumbar puncture. 
Other non-neurological complications 
accounted for an additional 1%. These 
included pneumothorax, shoulder, chest and 
pleuritic pain, hiccoughing and hematuria. 
Yan and Myers found no significant difference 
in nausea, vomiting, diarrhea and sedation 
among treatment groups, but constipation was 
significantly less in NCPB group.66 Orthostatic 
hypotension was more common in the NCPB 
group, but the difference between treatment 
groups was not statistically significant (p = 
0.09). 
Recently, a meta-analysis was performed for 
analyzing diarrhea, constipation, hypotension, 
and nausea and vomiting for percutaneous 
NCPB.69 The incidence of diarrhea (p = 
0.0003) and hypotension (p = 0.0003) were 
significantly higher in NCPB than SAT. The 
results were not surprising as sympatholytic 
agents were known to cause hypotension. 
Diarrhea was common due to unopposed 
stimulation of the parasympathetic nervous 
system.86 Conversely, the incidence of 
constipation, nausea and vomiting were 
significantly lower in NCPB than SAT (p < 
0.0001), suggesting opioid-sparing effect of 
NCPB.66 
Other less common side effects included local 
pain at needle puncture site (7-29%), back 
pain (5-60%), shoulder pain (6-9%), signs of 
alcohol intoxication (7-22.4%), pneumothorax 
(1-3%), reactive pleurisy or pleural effusion 
(5-8%), transient dysesthesias (0.3-7%), 
transient neuritis (2-37%), permanent 
foot drop (1.5%), transient monoparesis 
(0.3%), peritonitis (6%) and hematuria (<2-
6%)66. Permanent, partially reversible and 
completely reversible paraplegia have also 
been reported.66 
Davies conducted a survey of 160 pain 
clinics in England and Wales that performed 
NCPB over a 5 year period (1986-1990) 
They noted that 4 out of 2730 NCPB 
patients developed permanent paraplegia.87 
Postulated mechanisms for the resulting 
paraplegia included inadvertent seepage 
or injection of neurolytic agent into the 
cerebrospinal fluid and impaired blood supply 
to the spinal cord due to injury or spasm of 
the artery of Adamkiewicz. The estimated 
incidence of permanent paraplegia accounted 
for approximately 0.15%. Other rare 
complications such as sexual dysfunction,88 
retroperitoneal hematoma,89 abdominal aortic 
dissection,90 chylothorax,91 diaphragmatic 
paralysis,92 and hemorrhagic gastritis and 
duodenitis93 had all been reported. Despite 
considerable risks of major complications, 
NCPB is widely considered to be a safe 
procedure because operative mortality 
and catastrophic complications remain 
exceedingly rare.  
Conclusion
Neurolytic blockade of the celiac/splanchnic 
plexus can be used safely in cancer patients 
for analgesic control. It provides superior 
pain control and an analgesic-sparing effect 
in patients with advanced intraabdominal 
malignancies up to six months, particularly 
when combined with SAT. At the present 
time, the data concerning NCPB for improved 
survival and QoL are inconsistent and less 
compelling. There is also no evidence of 
superiority for neurolysis of celiac plexus 
or splanchnic nerves. Predictive factors 
contributing to the efficacy of NCPB include 
disease progression, metastases, operator 
experience, location of tumor, tumor burden 
and injectate spread. The use of alcohol and 
phenol appear to be equally effective for 
cancer-related pain relief. The optimal volume 
of neurolytic agent remains controversial, but 
40 ml of alcohol appears to yield adequate 
extent of longitudinal spread along the celiac 
axis. We conclude that early application of 
NCPB should be encouraged to serve as 
a supplement to multimodal analgesia for 
malignant pain in patients with advanced 
disease. The decision to employ NCPB should 
always be individualized, by incorporating 
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